Loading
Threading a catheter into the artery feeding a liver tumour and injecting chemotherapy plus particles that block the blood supply, starving and poisoning it at once.
The standard treatment for intermediate-stage (BCLC B) hepatocellular carcinoma that cannot be resected, ablated or transplanted, exploiting the fact that tumours draw blood from the hepatic artery while normal liver relies on the portal vein. Drug-eluting beads deliver doxorubicin more slowly than conventional lipiodol emulsions. Combining TACE with immunotherapy and anti-VEGF drugs (EMERALD-1, LEAP-012) improves progression-free survival, and TACE is also used to bridge patients to liver transplantation.
Shares TARE / SIRT (radioembolisation with yttrium-90), BCLC staging, Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
Shares EMERALD-1, Transarterial chemoembolisation (TACE), Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma.
Shares Transarterial chemoembolisation (TACE), Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma.
Shares Transarterial chemoembolisation (TACE), Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma.
Shares Transarterial chemoembolisation (TACE), Intermediate hepatocellular carcinoma (BCLC B), Lenvatinib, Hepatocellular carcinoma.
Shares Transarterial chemoembolisation (TACE), Intermediate hepatocellular carcinoma (BCLC B), Lenvatinib, Hepatocellular carcinoma.
Shares EMERALD-1, Intermediate hepatocellular carcinoma (BCLC B).
Shares BCLC staging, Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.